Melanoma Research Alliance (MRA): Multiple opportunities

*MRA Established Investigator Academic-Industry Partnership Awards: Intended for investigators with an established record of scientific productivity. Preliminary data required. A letter of support from industry is required. Funding: from MRA $100K over 2-3 years. Industry funds and/or in-kind support (e.g., reagents, clinical grade drugs, equipment, contract services) must match but may exceed MRA funds.
*Amgen-MRA Established Investigator Academic-Industry Partnership Award: Preclinical or correlative laboratory studies related to the therapeutic potential of oncolytic virus immunotherapy in melanoma, alone or in combination with immune modulators (e.g., checkpoint inhibitors) or targeted therapies. Of particular interest: Potential biomarkers of response in local and distant tumors and immune cell-type identification/evaluation in tumors and systemic changes related to oncolytic virus immunotherapy treatment. Mechanism of action studies using in vivo imaging or molecular techniques to differentiate direct versus immune-mediated effects are encouraged. Funding: Up to $200,000 per year for 2 to 3 years. A letter of support from Amgen is required.
*Bristol-Myers Squibb-MRA Team Science Awards in Immunotherapy: Multidisciplinary teams of two or more established PIs to conduct projects with the potential to lead to transformative advances in melanoma immunotherapies. Up to $900,000 over 2 to 3 years may be requested.
*MRA Team Science Academic-Industry Partnership Awards: These awards are designed to facilitate progress via interactions between the academic and industrial research sectors in the multidisciplinary team setting. Funding: up to $500,000 total over 2 to 3 years from MRA. Industry funds and/or in-kind support (e.g., reagents, clinical grade drugs,
equipment, contract services) must match but may exceed MRA funds.
http://www.curemelanoma.org/research/request-for-proposals/

http://www.curemelanoma.org/assets/2014-2015-RFP.pdf